This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Register by January 24 to save up to $1200

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 19-22, 2025
Manchester Grand Hyatt San DiegoSan Diego, CA

Guillaume Jacquot, PhD
Program Director, Brain and Tissue Delivery of Oligonucleotides at Vect-Horus
Speaker

Profile

Dr. Guillaume JACQUOT is Doctor of Pharmacy and got his PhD in cellular biology. He brings 20 years of academic and industrial experience in multi-disciplinary scientific project lead and translational research in various fields, including intracellular trafficking, virology, cardiovascular, neurobiology and cancer. His expertise extends from early discovery and hit-to-lead optimization to regulatory pharmacology and preclinical/early clinical development. He joined VECT-HORUS in 2010 where he established internal resources dedicated to intracellular pharmacokinetics (ICPK) profiling and pharmacology of molecular conjugates targeting endocytic receptors and in vivo evaluation of PK and pharmacological properties of lead candidates. Since 2016, he is leading efforts to apply and optimize VECT-HORUS’ VECTrans® drug targeting technology to therapeutics oligonucleotides to explore and implement their full potential in clinics based on industrial partnerships.

Agenda Sessions

  • VECTrans® Platform Achieves Potent Functional Delivery of Oligonucleotides in NHP at Low Dose

    9:30am